This is a phase I, open-label, single-arm study conducted to evaluate the efficacy, safety and PK of CGC738 in the treatment of advanced clear cell renal cell carcinoma (ccRCC).

This is a single-arm, open-label study. This study will include two parts, dose escalation phase (3+3 design) followed by a dose expansion phase. All eligible participants will receive a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by CAR-T cell injection.

Additional patients will be enrolled in the dose expansion phase to further characterize the safety profile and evaluate the efficacy of anti-CD70 CAR-T cell injection.

Inclusion Criteria:

• 1. Age 18 to 75 years.
• 2.ECOG 0-1 points.
• 3. The expected survival time is more than 3 months.
• 4. Patients with advanced ccRCC confirmed by histology or cytology to be recurrent or metastatic after at least first-line treatment.
• 5. IHC: CD70 positive.
• 6. At least one measurable lesion at baseline per RECIST version 1.1.
• 7. The functions of important organs are basically normal:
• 8. Pregnancy tests for women of childbearing age shall be negative, both men and women agreed to use effective contraception.

Exclusion Criteria:

• 1. Use of cell therapy within the previous one month.
• 2. Subjects with other malignant tumors within the past 2 years, except basal or squamous skin cancer, superficial bladder cancer, and breast cancer in situ, have been completely cured and do not need follow-up treatment.
• 3. Patients with leptomeningeal metastasis or central nervous system metastasis, and definite central nervous system underlying diseases with significant symptoms.
• 4. Immunotherapy, targeted drug therapy or chemotherapy within 5 drug half-lives within 2 weeks before cell infusion.
• 5. Active hepatitis B, HIV positive and HCV positive.
• 6. Active infection or uncontrollable infection.
• 7. Uncontrollable or significant heart disease.
• 8. Unstable respiratory diseases, including interstitial pneumonia.
• 9. Uncontrolled ascites and pleural effusion.
• 10.Known to have active or uncontrolled autoimmune diseases, such as Crohns disease, rheumatoid arthritis, systemic lupus erythematosus, etc.
• 11.Subjects who are using systemic steroids or steroid inhalers for treatment.
• 12.Pregnant or lactating female subjects.
• 13.Other investigators deem it unsuitable to participate in the study